Does AHCCCS (Arizona Medicaid) Cover GLP-1 Weight Loss Drugs in 2026?

Last updated: June 25, 2026 | Reading time: ~8 minutes | Reviewed by Dr. Marcus Tan, MD

Direct answer — AHCCCS and GLP-1s in 2026

As of 2026, AHCCCS (Arizona’s Medicaid, pronounced “access”) covers GLP-1 medications for type 2 diabetes with prior authorization, but it does not cover them for weight loss — anti-obesity use is an explicit benefit exclusion that is denied as a “Plan Exclusion.” Wegovy and Zepbound prescribed purely to lose weight are not covered. The only non-diabetes GLP-1 pathways AHCCCS will pay for are Wegovy for cardiovascular-risk reduction (BMI of 30 or higher, no diabetes) and Wegovy for MASH liver disease (fibrosis stage F2/F3, specialist-prescribed). If your goal is weight loss alone and you do not have type 2 diabetes or one of those specific conditions, AHCCCS will not cover a GLP-1.

Important — verify your specific plan

Coverage rules, preferred drug lists, and prior-authorization criteria change. AHCCCS members are enrolled in an ACC managed-care plan — Mercy Care, Banner University Family Care, UnitedHealthcare Community Plan, Molina, Care1st/Wellpoint, Health Choice Arizona, or Arizona Complete Health — and all of them follow AHCCCS’s statewide PA and exclusion rules. Before you act on anything here, call the member services number on your AHCCCS plan card to confirm your current pharmacy benefit. This guide is educational and is not medical or legal advice.

AHCCCS GLP-1 coverage at a glance

Drug	FDA-Approved Indication	AHCCCS Coverage 2026	Prior Authorization?
Ozempic	Type 2 diabetes	Covered, non-preferred	PA
Wegovy	Weight management	NOT for weight loss; covered only for CV-risk or MASH	PA
Mounjaro	Type 2 diabetes	Covered, non-preferred	PA
Zepbound	Weight management + OSA	NOT covered – excluded	n/a
Trulicity	Type 2 diabetes	Covered, preferred	often
Exenatide	Type 2 diabetes	Covered, preferred	often

GLP-1s for type 2 diabetes on AHCCCS

For people with type 2 diabetes, AHCCCS does cover GLP-1 medications — but it manages them through a preferred drug list and prior authorization. The preferred agents are the ones AHCCCS wants prescribers to try first; the non-preferred agents require you to fail the preferred options before they will be approved.

Preferred: Trulicity, Victoza / generic liraglutide, and exenatide.
Non-preferred: Mounjaro, Ozempic (both the injection and the tablets), and Rybelsus.

Under the AHCCCS fee-for-service pharmacy prior-authorization criteria effective June 1, 2026, a GLP-1 for diabetes is approved only when all of the following are met:

A diagnosis of type 2 diabetes.
A baseline A1C of 6.5% or higher.
Failure of metformin at 1,500 mg/day or more for 90 days, or a documented contraindication or intolerance to metformin.
Age 10 or older (Ozempic requires age 18 or older).
The medication is not being used for weight loss.
The medication is not being taken together with a DPP-4 inhibitor.

Non-preferred injectables carry an additional step-therapy requirement: a 90-day trial and failure of Trulicity AND liraglutide AND exenatide before AHCCCS will approve Mounjaro or Ozempic. In short, you need genuine type 2 diabetes, a qualifying A1C, and a documented metformin trial — and for the brand-name injectables, a failed trial of the preferred GLP-1s as well.

Wegovy & Zepbound for weight loss on AHCCCS

This is the part that surprises most members. AHCCCS treats weight loss as a non-covered category for these drugs. In the program’s own words, “Wegovy when used for weight loss is excluded and denied as a benefit exclusion.” Zepbound is denied for weight loss — and also for obstructive sleep apnea — as a Plan Exclusion, and Saxenda is not covered at all. A Plan Exclusion is different from a routine denial: it means the benefit simply does not exist under your plan, so it cannot be overturned by proving medical necessity.

There are two narrow, non-diabetes pathways where a GLP-1 can still be covered, and both apply only to Wegovy:

Wegovy for cardiovascular-risk reduction: for members with a BMI of 30 or higher and no diabetes, to reduce the risk of cardiovascular events. This is the FDA-approved CV indication, not a weight-loss benefit — even though weight reduction is a side effect.
Wegovy for MASH (metabolic dysfunction-associated steatohepatitis): for members with liver fibrosis stage F2 or F3, when prescribed by a specialist.

A common myth is that AHCCCS covers Wegovy or Zepbound for weight loss as long as your BMI is 30 or higher. That is not true. The BMI-of-30 threshold applies only to Wegovy’s cardiovascular-risk indication. Arizona is also not one of the roughly 13 states that cover GLP-1s specifically for obesity, so do not assume a weight-loss approval is possible based on what another state does.

Ozempic/Mounjaro off-label for weight loss

Because Ozempic and Mounjaro are covered for diabetes, some members hope to get them approved “off-label” for weight loss. In practice, this does not work under AHCCCS. The prior-authorization criteria explicitly require a type 2 diabetes diagnosis, a baseline A1C of 6.5% or higher, and a documented metformin trial — and they explicitly state the drug must not be used for weight loss.

If you do not have type 2 diabetes, you cannot meet the A1C and metformin requirements, so the PA will be denied.
Submitting an Ozempic or Mounjaro request that lists weight loss as the indication will be denied as falling outside the covered criteria.
The honest path to coverage is either genuine, documented type 2 diabetes or — for Wegovy only — the cardiovascular-risk or MASH pathway when it truly applies to you.

What if AHCCCS denies your GLP-1?

The first thing to figure out is why you were denied, because that determines whether an appeal can succeed. Read your Notice of Adverse Benefit Determination carefully.

Plan Exclusion (weight-loss denial): if Wegovy or Zepbound was denied because it was requested for weight loss, that is a benefit exclusion. It is not overturnable on medical necessity, because the benefit does not exist. Appealing the same weight-loss request will not change the outcome.
Criteria denial (diabetes/PA): if a diabetes GLP-1 was denied because of missing documentation — for example, no recorded A1C, an incomplete metformin trial, or missing step-therapy records — that is fixable. Your prescriber can resubmit with the correct chart notes.

To appeal, file through your plan’s Grievance & Appeals process (for fee-for-service members, the AHCCCS Office of General Counsel). A standard appeal takes roughly 30 days; an expedited appeal, when your health could be seriously harmed by waiting, takes about 3 working days. If the plan upholds the denial, you can request a State Fair Hearing before an Administrative Law Judge. The most productive move is usually to pivot to a genuinely covered pathway — a documented diabetes request, or Wegovy for cardiovascular-risk or MASH — where it is clinically valid for you.

GLP-1 alternatives for AHCCCS members

If AHCCCS will not cover a GLP-1 for your situation, you still have options. Cash-pay telehealth programs offer compounded semaglutide or tirzepatide, often around $200-$400 per month. Note that compounded versions are not FDA-approved and are not AHCCCS-covered, and most manufacturer copay cards exclude people with Medicaid. Here are two telehealth programs members commonly compare:

Ro Body Program

A telehealth weight-management program with clinician oversight and medication options for eligible members, billed as a monthly cash-pay subscription separate from your AHCCCS coverage.

Remedy Meds

A cash-pay telehealth option offering compounded GLP-1 medication plans with transparent monthly pricing for people who do not have insurance coverage for weight loss.

See Remedy Meds pricing

Want a side-by-side look at costs and what's included? compare GLP-1 telehealth programs.

How to apply for prior authorization

If you may qualify for a covered pathway (type 2 diabetes, or Wegovy for CV-risk or MASH), here is how the prior-authorization process works:

Confirm which ACC plan you're enrolled in and call the member services number on your AHCCCS card to verify the current pharmacy criteria.
Make an appointment with your prescriber and bring documentation of your diagnosis, your most recent A1C, and your metformin history (dose, dates, and any side effects).
Ask your prescriber to submit the prior-authorization request to your plan with all required chart notes, including step-therapy trials for non-preferred drugs.
For non-preferred injectables, make sure the records show a 90-day trial and failure of Trulicity, liraglutide, and exenatide.
Watch for the plan's decision and read any Notice of Adverse Benefit Determination closely to see whether a denial is a fixable criteria issue or a Plan Exclusion.
If a covered request is denied on the criteria, work with your prescriber to correct the documentation and resubmit, then appeal if needed.

Frequently asked questions

Does AHCCCS cover Wegovy for weight loss?

No. AHCCCS excludes Wegovy when it is used for weight loss and denies it as a benefit exclusion. The only ways Wegovy is covered are for cardiovascular-risk reduction (BMI of 30 or higher, no diabetes) or for MASH liver disease (fibrosis F2/F3, specialist-prescribed) — not for weight loss on its own.

Does AHCCCS cover Ozempic?

Yes, for type 2 diabetes — Ozempic is a covered, non-preferred drug that requires prior authorization. You'll need a type 2 diabetes diagnosis, a baseline A1C of 6.5% or higher, a documented metformin trial, and (because it's non-preferred) a failed trial of the preferred GLP-1s. AHCCCS does not cover Ozempic for weight loss.

Does Mercy Care cover Mounjaro?

Mercy Care, like all AHCCCS ACC plans, follows AHCCCS's statewide rules. Mounjaro is covered as a non-preferred drug for type 2 diabetes with prior authorization, including step therapy through the preferred GLP-1s. It is not covered for weight loss.

Does AHCCCS cover Zepbound for weight loss or sleep apnea?

No. AHCCCS denies Zepbound for weight loss and also for obstructive sleep apnea as a Plan Exclusion. Because it's a benefit exclusion rather than a medical-necessity denial, it cannot be overturned on appeal.

What A1c do I need for AHCCCS to cover a GLP-1?

The AHCCCS criteria require a baseline A1C of 6.5% or higher (along with a type 2 diabetes diagnosis and a documented metformin trial). Note this is 6.5%, not 7% — but the A1C alone is not enough; all of the PA criteria must be met.

How do I appeal an AHCCCS GLP-1 denial?

First identify the reason. A weight-loss denial is a Plan Exclusion and can't be won on medical necessity. A diabetes criteria denial is fixable — resubmit with the right documentation. To appeal, file through your plan's Grievance & Appeals process (fee-for-service members use the AHCCCS Office of General Counsel); standard appeals take about 30 days and expedited appeals about 3 working days, followed by a State Fair Hearing before an Administrative Law Judge if needed.